Skin clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.